Levodopa for idiopathic restless legs syndrome: Evidence-based review

Movement Disorders

Volumn 22, Issue 13, 2007, Pages 1943-1951

  Conti, Cristiane Fiquene ^a   De Oliveira, Márcio Moysés ^a   Andriolo, Regis Bruni ^a   Saconato, Humberto ^a   Atallah, Alvaro Nagib ^a   Valbuza, Juliana Spelta ^a   De Carvalho, Luciane Bizari Coin ^a   Do Prado, Gilmar Fernandes ^a,b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Federal University of Sao Paulo ^*  (Brazil)

Author keywords

Augmentation; Levodopa; Restless legs syndrome; Systematic review

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; DEXTROPROPOXYPHENE; LEVODOPA; PERGOLIDE; PIRIBEDIL; PLACEBO; VALPROIC ACID;

ABNORMAL VISION; ACTIMETRY; ARTICLE; BEDTIME DOSAGE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRIVE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSPEPSIA; EVENING DOSAGE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HUMAN; IDIOPATHIC DISEASE; LONG TERM CARE; MUSCLE WEAKNESS; NAUSEA; NERVOUSNESS; NIGHTMARE; NOCTURIA; POLYSOMNOGRAPHY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESTLESS LEGS SYNDROME; SIDE EFFECT; SLEEP PATTERN; SPEECH; STOMACH PAIN; STRUCTURED QUESTIONNAIRE; SYSTEMATIC REVIEW; TACHYCARDIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

ANTIPARKINSON AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EVIDENCE-BASED MEDICINE; HUMANS; LEVODOPA; LONG-TERM CARE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESTLESS LEGS SYNDROME; TREATMENT OUTCOME;

EID: 36248978098     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21662     Document Type: Article

References (44)

1. Ekbom KA. Restless legs syndrome. Neurology 1960;10:868-873.
2. Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005;165:1286-1292.
3. Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4:101-109.
4. Picchietti D, Winkelman JW. Restless legs syndrome, periodic limb movements in sleep, and depression. Sleep 2005;28:891-898.
5. Trenkwalder C, Paulus W, Walters AS. The restless legs syndrome review. Lancet Neurol 2005;4:465-475.
6. Allen RP. Dopamine and iron in the pathophysiology of restless legs syndrome. Sleep Med 2004;5:385-391.
7. Cervenka S, Palhagen SE, Comley RA, et al. Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. Brain 2006;129 (Part 8):2017-2028.
8. Earley CJ, B Barker P, Horska A, Allen RP. MRI-determined regional brain iron concentrations in early- and late-onset restless legs syndrome. Sleep Med 2006;7:458-461.
9. Wetter TC, Eisensehr I, Trenkwa lder C. Functional neuroimaging studies in restless legs syndrome. Sleep Med 2004;5:401-406.
10. Tribl GG, Asenbaum S, Happe S, Bonelli RM, Zeitlhofer J, Auff E. Normal striatal D2 receptor binding in idiopathic restless legs syndrome with periodic leg movements in sleep. Nucl Med Commun 2004;25:55-60.
11. Michaud M, Soucy JP, Chabli A, Lavigne G, Montplaisir J. SPECT imaging of striatal pre- and postsynaptic dopaminergic status in restless legs syndrome with periodic leg movements in sleep. J Neurol 2002;249:164-170.
12. Trenkwalder C, Walters AS, Hening WA, et al. Positron emission tomographic studies in restless legs syndrome. Mov Disord 1999;14:141-145.
13. Turjanski N, Lees AJ, Brooks DJ. Striatal dopaminergic function in restless legs syndrome: 18F-dopa and HC-raclopride PET studies. Neurology 1999;52:932-937.
14. Connor JR, Boyer PJ, Menzies SL, et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology 2003;61:304-309.
15. Connor JR, Wang XS, Patton SM, et al. Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome. Neurology 2004;62:1563-1567.
16. Hening W. The clinical neurophysiology of the restless legs syndrome and periodic limb movements, Part 1: diagnosis, assessment, and characterization. Clin Neurophysiol 2004;115:1965-1974.
17. Trenkwalder C, Paulus W. Why do restless legs occur at rest? -pathophysiology of neuronal structures in RLS. Neurophysiology ofRLS (Part 2). Clin Neurophysiol 2004;115:1975-1988.
18. Hening WA, Allen RP, Earley CJ, Picchietti DL, Silber MH. Restless legs syndrome task force of the standards of practice committee of the American Academy of Sleep Medicine. An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 2004;27:560-583.
19. American Sleep Disorders Association. The international classification of sleep disorders: diagnostic and coding manual (revised edition). Rochester, MN: American Sleep Disorders Association; 1997.
20. The International Restless Legs Syndrome Study Group. Validation of the international restless legs syndrome study group rating scale for restless legs syndrome. Sleep Med 2003;4:121-132.
21. Akpinar S. Restless legs syndrome treatment with dopaminergic drugs. Clin Neuropharmacol 1987;10:69-79.
22. Montplaisir J, Boucher S, Gosselin A, Poirier G, Lavigne G. Persistence of repetitive EEG arousals (K-alpha complexes in RLS patients treated with L-dopa). Sleep 1996;19:196-199.
23. Brodeur C, Montplaisir J, Godbout R, Marinier R. Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study. Neurology 1988;38:1845-1848.
24. Saletu M, Anderer P, Högl B, et al. Acute double-blind, placebo-controlled sleep laboratory and clinical follow up studies with a combination treatment of rr-L-dopa and sr-L-dopa in restless legs syndrome. J Neural Transm 2003;110:611-626.
25. Von Scheele C. Levodopa in restless legs. Lancet 1986;2:426-427.
26. Trenkwalder C, Stiasny K, Pollmächer T, et al. L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial. Sleep 1995;18:681-688.
27. Kaplan PW, Allen RP, Buchholz DW, Walters JK. A double-blind, placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene. Sleep 1993;16:717-723.
28. Staedt J, Wassmuth F, Ziemann U, Hajak G, Ruther E, Stoppe G. Pergolide: treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double-blind randomized crossover trial of pergolide versus L-Dopa. J Neural Transm 1997;104:461-468.
29. Eisensehr I, Ehrenberg BL, Rogge Solti S, Noachtar S. Treatment of idiopathic restless legs syndrome (RLS) with slow-release valproic acid compared with slow-release levodopa/benserazid. J Neurol 2004;251:579-583.
30. Becker PM, Jamieson AO, Brown WD. Dopaminergic agents in restless legs syndrome and periodic limb movements of sleep: response and complications of extended treatment in 49 cases. Sleep 1993;16:713-716.
31. Guilleminault C, Cetel M, Philip P. Dopaminergic treatment of restless legs and rebound phenomenon. Neurology 1993;43:445.
32. Von Scheele C, Kempi V. Long-term effect of dopaminergic drugs in restless legs. A 2-year follow-up. Arch Neurol 1990;47:1223-1224.
33. Montplaisir J, Godbout R, Poirier G, Bedard MA. Restless legs syndrome and periodic movements in sleep: physiopathology and treatment with L-dopa. Clin Neuropharmacol 1986;9:456-463.
34. Earley CJ, Allen RP. Pergolide and carbidopa /levodopa treatment of restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients. Sleep 1996;19:801-810.
35. Trenkwalder C, Collado Seidel V, et al. One-year treatment with standard and sustained-release levodopa: appropriate long-term treatment of restless legs syndrome? Mov Disord 2003;18:1184-1189.
36. Allen RP, Earley CJ, Augmentation of the restless legs syndrome with carbidopa levodopa. Sleep 1996;14:629-650.
37. Boivin DB, Montplaisir J, Poirier G. The effects of L-dopa on periodic leg movements and sleep organization in narcolepsy. Clin Neuropharmacol 1989;12:339-345.
38. Sandyk R, Bernick C, Lee SM, Stern LZ, Iacono RP, Bamford CR. L-dopa in uremic patients with the restless legs syndrome. Int J Neurosci 1987;35:233-235.
39. Walker SL, Fine A, Kryger MH. L-DOPA/carbidopa for nocturnal movement disorders in uremia. Sleep 1996;19:214-218.
40. Benes H, Kurella B, Kummer J, Kzenwadel J, Selzer R, Kohnen R. Rapid on set of action of levodopa in restless legs syndrome: a double-blind, randomized, multicenter, crossover trial. Sleep 1999;22:1073-1081.
41. Collado-Seidel V, Kazenwadel J, Wetter TC, et al. A controlled study of additional sr-L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms. Neurology 1999;52:285-290.
42. Wetter TC, Trenkwalder C, Stiasny K, et al. Treatment of idiopathic and uremic restless legs syndrome with L-dopa-a double-blind cross-over study. Wien Med Wochenschr 1995;145:525-527 (in German).
43. Quattrone A, Zappea M, Aguglia U, et al. The subacute levodopa test for evaluating long-duration response in Parkinson's disease. Ann Neurol 1995;38:389-395.
44. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol 2002;31:140-149.